Pages that link to "Q40314252"
Jump to navigation
Jump to search
The following pages link to Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis (Q40314252):
Displaying 50 items.
- BAG3: a new player in the heart failure paradigm (Q28088321) (← links)
- mTOR and cancer therapy (Q28268516) (← links)
- Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy (Q30419679) (← links)
- Apoptosis inhibition by Bcl-2 gives way to autophagy in glucocorticoid-treated lymphocytes (Q30538797) (← links)
- Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide (Q33414827) (← links)
- Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma (Q34218069) (← links)
- Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells (Q34311717) (← links)
- Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. (Q34387833) (← links)
- Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. (Q34632966) (← links)
- Activation of mTOR ameliorates fragile X premutation rCGG repeat-mediated neurodegeneration (Q34693311) (← links)
- Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma (Q35696506) (← links)
- The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence (Q36541067) (← links)
- MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies (Q36602853) (← links)
- mTOR, translation initiation and cancer (Q36623679) (← links)
- Investigational treatments for multiple myeloma (Q36654336) (← links)
- mTOR signalling in human cancer (Q36919646) (← links)
- PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma (Q37016007) (← links)
- Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas (Q37074284) (← links)
- Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (Q37247581) (← links)
- Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis (Q37341018) (← links)
- Targeted therapies in multiple myeloma (Q37431609) (← links)
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies (Q37432231) (← links)
- Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies (Q37598141) (← links)
- Novel therapeutic targets for multiple myeloma (Q37707383) (← links)
- Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies (Q37779489) (← links)
- Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations (Q37789771) (← links)
- Targeting autophagy during cancer therapy to improve clinical outcomes (Q37858077) (← links)
- The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma (Q37877729) (← links)
- Molecular mechanisms of effectiveness of novel therapies in multiple myeloma (Q38035044) (← links)
- Signaling Pathways and Emerging Therapies in Multiple Myeloma (Q38753307) (← links)
- Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy. (Q38895113) (← links)
- Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway (Q39010100) (← links)
- Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype (Q39380262) (← links)
- Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention (Q39548450) (← links)
- Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. (Q39718152) (← links)
- Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis (Q39718208) (← links)
- Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity (Q39748248) (← links)
- Synergistic effect of rapamycin and cisplatin in endometrial cancer cells (Q39844530) (← links)
- Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. (Q39896259) (← links)
- Targeting aurora kinases as therapy in multiple myeloma (Q40184968) (← links)
- Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma (Q40202733) (← links)
- AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells (Q40224641) (← links)
- Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. (Q42141137) (← links)
- Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells (Q42142241) (← links)
- mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein (Q42430902) (← links)
- Potential of mTOR inhibitors as therapeutic agents in hematological malignancies (Q42807577) (← links)
- Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis (Q43777184) (← links)
- Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. (Q46820379) (← links)
- Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression (Q48096856) (← links)
- PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. (Q48263465) (← links)